New imaging agent aims to spot Hard-to-Find tumors
NCT ID NCT06735560
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing a new radioactive tracer called 89Zr-TLX250, which targets a protein (CAIX) found on certain tumor cells. The goal is to see if PET-CT scans using this tracer can detect more tumor lesions in people with liver cancer, bile duct cancer, or neuroendocrine tumors compared to standard imaging. The study will enroll 60 adults and also monitor for any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
89Zr-TLX250 (a radioactive tracer for PET imaging)
What this could lead to
If successful, this could provide a more accurate imaging method for detecting these tumors, potentially guiding better treatment decisions.
What could go wrong
This is a small, early pilot study with only 60 participants. The tracer may not detect all tumors as hoped, and there are risks from radiation exposure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AP-HP - Site de Beaujon
NOT_YET_RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Nantes
RECRUITINGNantes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••